CCM
TRIB

Covington Capital Management’s Trinity Biotech TRIB Stock Holding History

Covington Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-14
Closed -$2K – 793
2020
Q1 		$2K Hold
14
– – ﹤0.01% 727
2019
Q4 		$2K Sell
14
-8
-36% -$1.14K ﹤0.01% 858
2019
Q3 		$4K Buy
+22
New +$5.73K ﹤0.01% 752

Other funds holding TRIB

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Covington Capital Management's TRIB Position: Q2 2020 in Review

Covington Capital Management sold out of Trinity Biotech (TRIB) in Q2 2020, closing a stake of 14 shares — an estimated $2K sold.

Covington Capital Management first reported a position in TRIB in Q3 2019 and held it in 3 quarters. The position peaked at $4K in Q3 2019. 26 funds tracked by Wall St. Rank hold TRIB as of Q2 2020.

  • Covington Capital Management reported no remaining Trinity Biotech position as of Q2 2020 after selling out during the quarter.
  • Covington Capital Management sold 14 Trinity Biotech shares in Q2 2020, an estimated $2K.
  • Covington Capital Management first reported a position in Trinity Biotech in Q3 2019 and held it in 3 quarters.
  • Covington Capital Management's Trinity Biotech position peaked at $4K in Q3 2019.
  • 26 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2020.

Based on Covington Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.